TWI757753B - 柳菩林（ｌｅｕｐｒｏｌｉｄｅ）組合物及用其治療乳癌之方法 - Google Patents

柳菩林（ｌｅｕｐｒｏｌｉｄｅ）組合物及用其治療乳癌之方法 Download PDF

Info

Publication number
TWI757753B
TWI757753B TW109117742A TW109117742A TWI757753B TW I757753 B TWI757753 B TW I757753B TW 109117742 A TW109117742 A TW 109117742A TW 109117742 A TW109117742 A TW 109117742A TW I757753 B TWI757753 B TW I757753B
Authority
TW
Taiwan
Prior art keywords
composition
acetate
lactide
breast cancer
release composition
Prior art date
Application number
TW109117742A
Other languages
English (en)
Chinese (zh)
Other versions
TW202110472A (zh
Inventor
約翰 密道頓
艾維納許 那及亞
約翰 亞瑟 麥克蘭尼
泰瑞 Ｌ 摩頓
Original Assignee
愛爾蘭商托爾瑪國際有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商托爾瑪國際有限公司 filed Critical 愛爾蘭商托爾瑪國際有限公司
Publication of TW202110472A publication Critical patent/TW202110472A/zh
Application granted granted Critical
Publication of TWI757753B publication Critical patent/TWI757753B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW109117742A 2019-05-27 2020-05-27 柳菩林（ｌｅｕｐｒｏｌｉｄｅ）組合物及用其治療乳癌之方法 TWI757753B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27
US62/853,153 2019-05-27

Publications (2)

Publication Number Publication Date
TW202110472A TW202110472A (zh) 2021-03-16
TWI757753B true TWI757753B (zh) 2022-03-11

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109117742A TWI757753B (zh) 2019-05-27 2020-05-27 柳菩林（ｌｅｕｐｒｏｌｉｄｅ）組合物及用其治療乳癌之方法

Country Status (17)

Country Link
US (2) US12453754B2 (enExample)
EP (1) EP3975990A1 (enExample)
JP (1) JP7664855B2 (enExample)
KR (1) KR20220041782A (enExample)
CN (1) CN114144169A (enExample)
AR (1) AR119021A1 (enExample)
AU (1) AU2020284587B2 (enExample)
BR (1) BR112021023904A2 (enExample)
CA (1) CA3141456A1 (enExample)
EA (1) EA202193257A1 (enExample)
IL (1) IL288503A (enExample)
MX (1) MX2021014540A (enExample)
PH (1) PH12021552976A1 (enExample)
SG (1) SG11202112888RA (enExample)
TW (1) TWI757753B (enExample)
UY (1) UY38717A (enExample)
WO (1) WO2020240417A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144169A (zh) 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
DK4135830T3 (da) 2020-12-23 2024-10-28 Tolmar International Ltd Systemer og fremgangsmåder til blanding af sprøjteventilanordninger
CN115518144A (zh) * 2021-06-26 2022-12-27 王婧宜 一种含有亮丙瑞林或其衍生物的口服药物组合物
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
JP4259610B2 (ja) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
DK3660073T3 (da) * 2007-02-15 2023-09-18 Tolmar International Ltd Poly(lactid-co-glycolid) med lav sprængning
DE202009010095U1 (de) 2009-07-24 2009-10-22 Chang, Ti-Li, Houli Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter
IL301603A (en) * 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
CN114144169A (zh) 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
KR102162217B1 (ko) 2020-05-07 2020-10-06 주식회사 파인비엠 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트
DK4135830T3 (da) 2020-12-23 2024-10-28 Tolmar International Ltd Systemer og fremgangsmåder til blanding af sprøjteventilanordninger
AU2022331238A1 (en) 2021-08-19 2024-02-01 Carefusion 303, Inc. Pivc-integrated hemolysis-reduction accessories with anti-spillage component for direct blood draw
FR3131618A1 (fr) 2021-12-30 2023-07-07 Parker Hannifin Emea Sarl Dispositif de raccordement aseptique d’un tube

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Harish B. Ravivarapu et al., "Sustained Activity and Release of Leuprolide Acetate from an In Situ Forming Polymeric Implant", AAPS PharmSciTech 2000; 1(1) article 1; *
Harish B. Ravivarapu et al., "Sustained suppression of pituitary‐gonadal axis with an injectable, in situ forming implant of leuprolide acetate", J Pharm Sci, Volume 89, Issue 6, P732-741, June 01, 2000 *

Also Published As

Publication number Publication date
WO2020240417A1 (en) 2020-12-03
KR20220041782A (ko) 2022-04-01
MX2021014540A (es) 2022-04-12
AR119021A1 (es) 2021-11-17
TW202110472A (zh) 2021-03-16
IL288503A (en) 2022-01-01
SG11202112888RA (en) 2021-12-30
AU2020284587A1 (en) 2022-01-06
UY38717A (es) 2020-11-30
US12453754B2 (en) 2025-10-28
EA202193257A1 (ru) 2022-03-10
PH12021552976A1 (en) 2022-07-04
AU2020284587B2 (en) 2025-09-18
BR112021023904A2 (pt) 2022-02-01
US20220265760A1 (en) 2022-08-25
US20260027176A1 (en) 2026-01-29
JP2022535694A (ja) 2022-08-10
JP7664855B2 (ja) 2025-04-18
EP3975990A1 (en) 2022-04-06
CA3141456A1 (en) 2020-12-03
CN114144169A (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
TWI757753B (zh) 柳菩林（ｌｅｕｐｒｏｌｉｄｅ）組合物及用其治療乳癌之方法
US11229599B2 (en) Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
KR102047634B1 (ko) 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
CN100464736C (zh) 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EA046538B1 (ru) Применение лейпролида для подавления функции яичников у субъекта с гормон-рецептор-положительным раком молочной железы
EP3746047A1 (en) Injectable composition
US11110303B2 (en) Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
CN120361228B (zh) 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物
JP4020256B2 (ja) 前立腺癌の局所治療剤
US20240207272A1 (en) Combinatorial targeted therapy methods
JP2026505783A (ja) 腫瘍を治療するためのパクリタキセルカチオンリポソームの使用
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
CN100431607C (zh) 一种抗实体肿瘤的药物组合物
WO2024206077A2 (en) Dosing regimes and combination therapies using archexin for the treatment of cancer
CN100500220C (zh) 一种含血管抑制剂的抗实体肿瘤药物组合物
CN119950404A (zh) 一种阴道用靶向脂质体温敏凝胶的制备方法及应用
CN101297970A (zh) 同载抗代谢药物及其增效剂的抗癌缓释注射剂
WO2019110688A1 (en) A composition comprising degarelix for use in the treatment of breast cancer
CN101336898A (zh) 同载铂类药物及其增效剂的抗癌缓释剂
CN101380306A (zh) 一种复方铂类药物缓释剂
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane
CN101380297A (zh) 复方铂类药物缓释剂
CN101283974A (zh) 一种抗癌缓释凝胶注射剂及其制备方法